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A B S T R A C T
Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor
cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in
NSCLC, while the composition of the immune cells (IC) in the tumor microenvironment including PD-L1+ cells
is believed to predict responses in tumors of some other primary sites. Total mutational load (TML) and mi-
crosatellite instability (MSI) also play a role in response to the immune checkpoint blockade. We investigated
immune microenvironment characteristics (PD-1, PD-L1, CD8) of 257 lung biopsies including 81 primary
(NSCLC) and 176 metastatic tumors to the lungs. TML and MSI were calculated from massively parallel se-
quencing (592-gene panel). TC expression of PD-L1 was more common in NSCLC than in metastatic carcinomas
(28% vs. 10%, p = 0.009), while PD-L1-positive IC were present at relevant percentages (1–5%) exclusively in
metastatic carcinomas (31% IC positive vs. 0%, p < 0.001). Metastatic carcinomas carried significantly lower
TML in comparison with the NSCLCs (6.6 mutations on average vs. 10, p = 0.01). All primary NSCLC were
microsatellite stable, and only 2 metastatic carcinomas exhibited MSI-H status. The number of PD-1+ and
CD8+ tumor infiltrating lymphocytes did not differ significantly between the primary and metastatic carci-
nomas. Our study revealed significant differences in tumor immune microenvironment (PD-L1 in IC and TC), and
its relationship to TML between NSCLC and metastatic cancers. These differences could determine the choice of a
predictive biomarker test and subsequently effect(s) of the immune therapy treatments in various advanced
cancers.
1. Introduction
Immune checkpoint inhibitors have improved cancer treatment in
the recent years, with significant survival benefits in advanced malig-
nancies of diverse lineages (e.g. melanoma, non-small cell lung cancer
[NSCLC], renal cell carcinoma, bladder carcinoma, classical Hodgkin
lymphoma). Tumor expression of CD274 (programmed cell death 1 li-
gand 1 or PD-L1) is the most commonly used predictive biomarker for
selection of patients for immune check point inhibition, but it is still in
need of refinement, particularly differentiating its expression on cancer
cells and in the immune cells of the tumor environment [1].
Suppression of the programmed cell death 1 (PD1 encoded by
PDCD1gene), expressed on activated T-lymphocytes by its ligands PD-
L1 and PD-L2 (CD273, PDCD1LG2) represent a major im-
munosuppressive mechanism in the tumor microenvironment [2].
Blockade of that inhibition may reactivate T-cell function and induce
their antineoplastic activity [2,3]. PD-L1 expression, measured by im-
munohistochemistry, can be found in both tumor (cancer) cells (TC)
and inflammatory/reactive “immune” cells (IC), and TC of PD-L1has
been successfully used to select patients for immune check point in-
hibitors [4-6]. However, a subset of PD-L1 TC-negative tumors may still
respond to the PD-1/PD-L1 blockade while failure to the therapy has
been observed in some PD-L1 TC-positive cancers [1]. Therefore, sub-
stantial efforts have been invested in refining existing and identifying
additional biomarkers that would predict patients' responses to the
immune checkpoint inhibition. Consequently, in recurrent and meta-
static bladder (urothelial) carcinomas, expression of PD-L1 on immune
cells (IC) had been described as a better predictive biomarker to ate-
zolizumab [3,7]. Among other potential predictive biomarkers, in-
creased CD8+ T-cell density and PD-1 overexpression on T-cells, have
been investigated [1,2,8-10]. Most recently, an increased expression of
the cancer neoantigens and measurement of tumor mutational load and
microsatellite instability have emerged as the potent predictors of the
response to the immune check point blockade therapies [11,12].
While PD-L1 expression in cancer cells (TC) of the NSCLC has been
particularly well characterized, PD-L1 in cancers metastatic to lungs
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(the most common site of dissemination for numerous malignancies)
was not. We comparatively analyzed distribution of PD-L1 along with
PD-1 and CD8 in neoplastic (TC) and immune cells (IC) of the tumor
microenvironment between primary (NSCLC) and metastatic tumors to
the lung (carcinomas, sarcomas, melanomas) in order to gain insight in
their differences which could lead to improved selection and treatment
outcomes for both primary lung carcinomas and for a wide variety of
disseminated malignancies.
2. Materials and methods
2.1. Samples
Two-hundred fifty seven formalin-fixed paraffin-embedded tissue
samples (81 NSCLC and 176 metastatic tumors to the lung) were pro-
filed at the CLIA/CAP/ISO-certified laboratory (Caris Life Sciences,
Phoenix, AZ). Histologic diagnosis for all cases was confirmed by a
board certified pathologist (Z.G.) and appropriate slides were used for
molecular profiling.
Caris Life Sciences maintains a de-identified database that houses
commercial laboratory results stripped of identifiers. The tumor pro-
filing data for this study was obtained from this de-identified database.
This analysis was retrospective and only consisted of results that were
already stored in the database. This research was compliant with 45
CFR 46.101(b). Therefore, the project was deemed exempt from IRB
oversight and consent requirements were waived.
2.2. Immunohistochemistry
The samples were evaluated for PD-L1 (SP142 antibody), PD-1
(NAT105 antibody), and CD8 expression (SP57 antibody) using auto-
mated immunohistochemical (IHC) staining methods. Expression of 4
mismatch repair proteins (MMRP) was tested in selected cases (equi-
vocal microsatellite result in NGS analysis) by IHC (MLH1, M1 anti-
body; MSH2, G2191129 antibody; MSH6, 44 antibody; PMS2, EPR3947
antibody).
PD-L1 positivity was defined as expression of membranous staining
at ≥5% cells in TCs or ICs as suggested earlier [13-16]. Due to the
observed low PD-L1 expression in IC (none of the tumors had PD-L1
positivity in ICs exceeding 5%), when IC was statistically analyzed
alone we dichotomized PD-L1 IC variable into two categories (< 1%
= negative and ≥1% = positive).
PD-1 and CD8 expressions were investigated in the IC (T-lympho-
cytes, histiocytes and dendritic cells) component. Whenever possible,
ten consecutive tumor fields were microscopically reviewed under 40×
objective (high-power field, hpf) and the total number of PD-1+ and
CD8+ cells was recorded. In case of small biopsies, the whole slides
were evaluated for both markers. Mean cohort values for both variables
were used for dichotomization in the statistical analysis.
All cases were further stratified into 4 categories based on the
presence or absence of PD-L1 expression on TC or ICs (tumor micro-
environment, TME, Table 4) [17].
All cases were evaluated by 2 investigators (W.S. and board-certi-
fied pathologist Z.G.); discordances in interpretations were resolved at
the double headed microscope evaluation.
2.3. Next-generation sequencing (NGS)
Tumor mutational load (TML) was calculated using the massively
parallel (next-generation) sequencing (Illumina NextSeq platform).
Only missense mutations that were not previously reported as germline
variants were used for TML estimation. NGS panel included 592 genes
(list of the genes is available here: http://www.
carismolecularintelligence.com/solid_tumors_international).
The TML variable was categorized as follows: Low TML (≤ 6); in-
termediate (7-16) and high TML (≥17). This categorization was
previously validated, based on the microsatellite instability (MSI) and
NGS data comparisons (available here: http://www.carislifesciences.
com/platforms/cmi-overview/total-mutational-load-tml/).
Microsatellite instability (MSI) status was determined by sequence
analysis of microsatellite repeat tracts in 7317 target loci in the 592-
gene panel.
2.4. Statistical methods
The two-tailed Fisher exact test and χ2 test were applied for the
correlation between the variables (p≤ 0.05).
3. Results
3.1. Patients and tumor sample characteristics
The study included the samples from 120 male and 137 female
patients (mean age: 62.4 for male and 62.6 for female patients; ranges:
12–90 years for male and 7–95 years for female patients).
The histologic subtypes of primary NSCLC included 15 squamous
cell carcinomas, 61 adenocarcinomas and 5 other NSCLCs (two ade-
nosquamous, 2 large cell carcinomas and one NSCLC not further spe-
cified). Metastatic tumors to the lung, most commonly included carci-
nomas (n = 126), including colon (n = 51), gynecologic (n = 22),
breast (n = 21), head and neck (n = 15), pancreas (n = 10) and
kidney (n = 7) primary sites; the remaining 50 metastatic tumors in-
cluded 15 soft tissue sarcomas, 11 malignant melanomas and 24 cases
of miscellaneous histologic types of solid cancers.
Types of specimens submitted for evaluation included 169 small
(needle) biopsies (51 NSCLC and 118 metastatic tumors) and 88 sur-
gically resected samples (30 NSCLC and 58 metastatic tumors)
(p = 0.57).
3.2. PD-L1 expression in primary (NSCLC) and metastatic tumors to the
lung
The results of PD-L1 expression in TC and IC are summarized in
Tables 1–3 and illustrative cases of primary NSCLC and metastatic
colorectal carcinoma are shown on Figs. 1–2. Specimen type (small vs.
surgical biopsy) had no influence on frequency of PD-L1 expression in
TCs and ICs (p = 0.23 and 0.86, respectively).
Overall, TC PD-L1 positivity in primary NSCLC was observed in 23
of 81 cases (28%) and in 24 of 176 metastatic tumors (14%)
(p = 0.009, Fisher's exact test). Among the 24 positive metastatic tu-
mors, 13 were carcinomas (Table 1). Interestingly, all three PD-L1+
breast carcinomas were triple-negative (ER-/PR-/Her2-) carcinomas
while 5 out of six head and neck carcinomas were squamous cell car-
cinomas. In non-carcinomatous metastases, PD-L1 expression was also
observed in 4/11 (36%) metastatic melanomas and 3/12 (20%) soft
tissue sarcomas (Table 1).
In adjacent normal lung tissue, PD-L1 expression was observed in
alveolar macrophages (positive internal control cell type). However,
PD-L1 expression in intratumoral IC was generally low in both cohorts
(none of the tumors had IC PD-L1 above 5%).
However, when> 1% IC threshold for positivity was applied, a
significantly higher proportion of IC PD-L1staining was observed in
metastatic carcinomas than in primary NSCLCs (31% vs. 0%)
(p < 0.001) (Tables 1). Notably, other histologic types of metastatic
tumors (e.g. melanomas and sarcomas) also showed significantly higher
IC PD-L1 expression (13–36% of cases) than NSCLCs. Consequently,
tumor immune microenvironment (TME) categories differed sig-
nificantly between the primary NSCLC and metastatic carcinomas to the
lung (Table 3) (see Fig. 3).
No significant difference in TC PD-L1 expression was observed
within the two major primary NSCLC subgroups (adenocarcinoma vs.
squamous cell carcinoma, p = 0.19, Table 1) whereas significant
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differences in TC PD-L1 expression were seen among the metastatic
carcinomas based on their lineages (from 0% positivity in pancreatic to
40% positivity in head and neck carcinomas, Table 1).
3.3. Relationship between the PD-L1 expression and tumor mutational load
(TML)
Tumor mutational load (TML) was analyzed in 229 samples (76 NSCLC
and 153 metastatic tumors). The NSCLC cases exhibited significantly higher
TML in comparison with the metastatic carcinomas (10 mutations on
average vs. 6.6, p < 0.001, Table 4). Also, PD-L1 TC positive NSCLCs had
higher TML compared with the PD-L1 negative primary tumors (p = 0.05).
MSI status was evaluated in 256 cases total; only two metastatic
tumors (1.3%) to the lung (one endometrial carcinoma and one ade-
nocarcinoma of presumably intestinal origin) exhibited MSI-H status.
None of the NSCLC (0%) had MSI-H (three equivocal cases by NGS had
intact MMRP expression by IHC).
No significant differences in TML were observed between the var-
ious histologic types in the metastatic carcinomas group. However,
metastatic melanomas (n = 10) had particularly high TML with an
average of 32.7 mutations (range, 1–130 mutations) (Table 4).
3.4. PD-1 and CD8 expression in primary (NSCLC) and metastatic tumors
to the lung
The mean number of CD8+ IC cells per 10 hpf/whole slides (small
biopsies) was 388 (range, 3 to> 3000) while the mean number of PD-1
positive cells was 33.7 (range, 0 to 280). The average number of PD-1+
and CD8+ ICs did not differ significantly between the primary and
metastatic tumors to the lung (p = 1.0 and 0.13, respectively)
(Table 2). A good correlation between PD-1+ and CD8+ cells (T-
Table 1
PD-L1 expression in tumor cells was significantly higher in NSCLC compared with the
metastatic carcinomas (p=0.003) while IC within metastatic tumors exhibited sig-
nificantly higher PD-L1 expression (p < 0.001).
Histotype PD-L1 expression in tumor cells Total
[< 5%] [≥5%]
NSCLC 58 (72%) 23 (28%) 81
- Adenocarcinoma 44 (72%) 17 (28%) 61
- Squamous cell carcinoma 11 (73%) 4 (27%) 15
- Other NSCLC 3 (60%) 2 (40%) 5
Metastatic carcinomas 113 (90%) 13 (10%) 126
- Colorectal carcinoma 49 (96%) 2 (4%) 51
- Gynecologic carcinomas 21 (95%) 1 (5%) 22
- Breast carcinoma 18 (86%) 3 (14%) 21
- Head and neck carcinomas 9 (60%) 6 (40%) 15
- Pancreatic carcinoma 10 (100%) 0 (0%) 10
- Renal cell carcinoma 6 (86%) 1 (14%) 7
Other metastatic tumors 39 (78%) 11 (22%) 50
- Soft tissue tumors 12 (80%) 3 (20%) 15
- Malignant melanoma 7 (64%) 4 (36%) 11
- Other cancers 20 (83%) 4 (17%) 24
Total 210 47 257
Histotype PD-L1 expression in inflammatory cells Total
[< 1%] [≥1%]
NSCLC 81 (100%) 0 (0%) 81
- Adenocarcinoma 61 (100%) 0 (0%) 61
- Squamous cell carcinoma 15 (100%) 0 (0%) 15
- Other NSCLC 5 (100%) 0 (0%) 5
Metastatic carcinomas 87 (69%) 39 (31%) 126
- Colorectal carcinoma 32 (63%) 19 (37%) 51
- Gynecologic carcinomas 16 (73%) 6 (27%) 22
- Breast carcinomas 13 (62%) 8 (38%) 21
- Head and neck carcinomas 12 (80%) 3 (20%) 15
- Pancreatic carcinoma 7 (70%) 3 (30%) 10
- Renal cell carcinoma 7 (100%) 0 (0%) 7
Other metastatic tumors 40 (81%) 10 (19%) 50
- Soft tissue tumors 13 (87%) 2 (13%) 15
- Malignant melanoma 7 (64%) 4 (36%) 11
- Other cancers 20 (80%) 4 (20%) 24
Total 208 49 257
Table 2
PD-1 and CD8 expression in inflammatory (T-cell) population [T-cell density] (mean
values were used to dichotomize both variables). The number of PD-1+ and CD8+ cells
did not differ significantly between the primary and metastatic tumors to the lung
(p=1.0 and 0.13, respectively).
Histotype PD-1 expression Total
Low (< 34) High (≥34)
NSCLC 55 (68%) 26 (32%) 81
- Adenocarcinoma 45 (74%) 16 (26%) 61
- Squamous cell carcinoma 8 (53%) 7 (47%) 15
- Other NSCLC 2 (40%) 3 (60%) 5
Metastatic carcinomas 40 (70%) 17 (30%) 57
- Colorectal carcinoma 17 (59%) 12 (41%) 29
- Gynecologic carcinomas 6 (67%) 3 (33%) 9
- Breast carcinoma 5 (71%) 2 (29%) 7
- Head and neck carcinomas 8 (100%) 0 (0%) 8
- Pancreatic carcinoma 2 (100%) 0 (0%) 2
- Renal cell carcinoma 2 (100%) 0 (0%) 2
Other metastatic tumors 21 (65%) 11 (35%) 32
- Soft tissue tumors 10 (71%) 4 (29%) 14
- Malignant melanoma 1 (33%) 2 (67%) 3
- Other cancers 10 (67%) 5 (33%) 15
Total 116 54 170
Histotype CD8 expression Total
Low (< 389) High (≥389)
NSCLC 53 (65%) 28 (35%) 81
- Adenocarcinoma 40 (65%) 21 (35%) 61
- Squamous cell carcinoma 9 (60%) 6 (40%) 15
- Other NSCLC 4 (80%) 1 (20%) 5
Metastatic carcinomas 44 (77%) 13 (23%) 57
- Colorectal carcinoma 19 (66%) 10 (34) 29
- Gynecologic carcinomas 9 (100%) 0 (0%) 9
- Breast carcinomas 5 (71%) 2 (29%) 7
- Head and neck carcinomas 8 (100%) 0 (0%) 8
- Pancreatic carcinoma 2 (100%) 0 (0%) 2
- Renal cell carcinoma 1 (50%) 1 (50%) 2
Other metastatic tumors 26 (81%) 6 (19%) 32
- Soft tissue tumors 13 (93%) 1 (7%) 14
- Malignant melanoma 1 (33%) 2 (67%) 3
- Other cancers 12 (80%) 3 (20%) 15
Total 123 47 170
Table 3
Significantly different TME categories between NSCLC and metastatic carcinomas to the
lung (p < 0.001).
Histotypes TME categories (PD-L1 expression) Total
TC+/IC+ TC-/IC- TC+/IC- TC-/IC+
NSCLC 0 (0%) 58 (72%) 23 (28%) 0 (0%) 81
Metastatic carcinomas 4 (3%) 78 (62%) 9 (7%) 35 (28%) 126
Total 4 136 32 35 207
TC = tumor cells; IC = inflammatory (immune cells); TME = tumor microenvironment;
NSCLC = non-small cell lung cancer.
W. Senarathne et al. Annals of Diagnostic Pathology 33 (2018) 62–68
64
lymphocytes) was also observed (p < 0.001, rs = 0.454). No sig-
nificant association between the number of CD8+ T-lymphocytes and
TML among the NSCLC and metastatic carcinomas was observed
(p = 0.59). No significant differences in presence of PD-1+ and CD8+
IC was observed between small (core) biopsies and resection samples
(p = 0.56 and 0.38, respectively).
4. Discussion
Immunotherapy with immune PD1/PD-L1 checkpoint inhibitors has
achieved remarkable therapeutic benefits in various solid and hema-
tologic malignancies [18,19]. However, predictive biomarkers still need
refinement [19]. A compelling body of evidence indicates that no single
biomarker may be sufficient to identify the optimal “PD-1/PD-L1 im-
munotype” in predicting the successful immune checkpoint treatment
strategy [2,9]. In the present study, we comparatively analyzed dis-
tribution of the two key targets of the immune checkpoint inhibitors in
a cohort of primary NSCLC and tumors metastatic to the lungs. Our data
support the previous results on the relatively common TC PD-L1 ex-
pression in NSCLC [20,21]. In contrast to the previous studies, we also
explored PD-L1 in IC that exhibited rare or no PD-L1 expression. On the
other hand, metastatic tumors were more commonly enriched by the
PD-L1+ IC cells with uncommon PD-L1 TC positivity. We did not have
a chance to perform the paired sample analysis comparing the meta-
static tumors' TME to their primary sites' TME, to observe dynamics of
the changes, if any. Couple of earlier studies indicated that some dis-
cordance in PD-L1 expression in TC of NSCLC can occur between the
primary and metastatic sites [22,23], but we are not aware of any such
studies outside NSCLC.
In NSCLC, PD-L1 expression level on tumor cells has been directly
correlated with response to anti-PD1/PDL1 immune checkpoint in-
hibitors. Low expression and high expression of PD-L1 testing is now
used in clinical practice to identify treatment-naïve and previously
treated patients most likely to obtain benefit from an anti-PD-1 therapy,
respectively [5,24]. On the other hand, the expression of PD-L1 on
tumor infiltrating lymphocytes may be important in identifying re-
sponders to specific anti-PDL1 immune checkpoint inhibitors, and a
combinatorial approach to evaluate PD-L1 expression on both tumor
cells and tumor infiltrating lymphocytes can help to identify responders
[3,25,26]. Even though the PD-L1 tumor expression is shown here to be
much lower in tumors metastatic to the lung compared to NSCLC, a
notably higher expression of PD-L1 expression on tumor infiltrating
immune cells was observed and may provide additional treatment op-
portunities for anti-PDL1 immune checkpoint inhibitors [26,27]. In
non-lung tumors, PD-L1 expression on tumor infiltrating immune cells
has been shown to help identify patient response [3,25,27]. Therefore,
our findings highlight the TME differences between primary and me-
tastatic tumors and reveal new therapeutic options in metastatic tu-
mors. Several recent studies showed a potential therapeutic benefit of
PD-1/PD-L1 blockade in locally advanced and/or metastatic tumors
enriched by the PD-L1+ ICs [3,7,13,28].
Regarding the different thresholds reported in literature for pre-
dictive value of PD-L1 in different tumor types, in our study we used the
uniform 5% threshold for PD-L1 positivity, because of the hetero-
geneous nature of both primary and metastatic cancers. Several clinical
trials and systematic reviews recommended 5% threshold
[5,15,16,29,30]; a systematic review with meta-analysis conducted by
Carbognin et al. revealed significant differences in therapeutic re-
sponses when 5% cutoff was used in the patients with NSCLC, geni-
tourinary cancers and malignant melanoma. No differences were ob-
served when 1% threshold was used [15].
Preliminary data indicate that the tumors with high levels of so-
matic mutations (TML) are more sensitive to PD-1/PD-L1 blockade
[1,18,31]. Our TML study revealed significantly higher TML in NSCLC
that in the metastatic carcinomas, which may predict their better re-
sponse to the immune therapy; of the metastatic tumors, metastatic
Fig. 1. Various PD-L1 expression in tumor cells in
primary (NSCLC) and metastatic tumor to the lung
(colorectal carcinoma).
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melanomas exhibited particularly high TML, which, in part, elucidate
their increased sensitivity to the PD-1/PD-L1 blockade. Interestingly, a
heterogeneous group of metastatic carcinomas to the lung showed no
significantly different TML.
Recently, tumor microsatellite instability has raised to the level of
lineage-agnostic biomarker of the response to the immune check point
inhibitors [12,32]. However, in our cohort, only a small proportion
(1.3%) of metastatic cancers and none of the primary NSCLC exhibited
MSI-H.
Beside its confirmed prognostic value, increased number of CD8+
T-lymphocytes within the tumor (“T-cell density”) has been proposed as
another biomarker associated with more favorable response to the
immune check point inhibitors [33,34]. Our study revealed no differ-
ences in the CD8+ T-cell density between the primary NSCLC and
Fig. 2. Various PD-L1 expression in inflammatory
(immune) cells in primary (NSCLC) and metastatic
tumor to the lung (colorectal carcinoma).
Fig. 3. PD-1 and CD8 distributions (T-lymphocytes) in a case of metastatic colorectal carcinoma (upper figures) and primary (NSCLC) (lower figures).
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metastatic tumors including metastatic carcinomas. Although a study of
Brown et al. indicated that immunogenic mutations in several solid
malignancies (lung, ovary, breast, colorectal, brain, and kidney cancer
in combined analysis) correlated with T-cell density, our study could
not confirm these observations [35]. Of note, our study included a re-
latively small number of metastatic breast, gynecologic and kidney
carcinomas, which may be a limiting factor for the statistical analysis
and comparisons.
Our study has several limitations. Firstly, we used a single mono-
clonal antibody (SP142 clone) to assess the status of PD-L1 in a wide
range of tumors and cell types. Although it was recently reported that
the sensitivity of the SP142 antibody was somewhat lower in detection
of IC in NSCLC [36], in our own laboratory utilizing a modified, vali-
dated laboratory developed test, SP142 performs comparably to 3 other
antibodies (SP263, 28-8, 22c3 antibodies) when all tumor types are
evaluated together [37] (Gatalica Z, manuscript in preparation). Fur-
thermore, SP142 is a widely used antibody clone with numerous studies
showing its utility not only to detect PD-L1 expression in TC but also to
predict a response to atezolizumab when measured in the immune cells
(IC) of the recurrent and metastatic urothelial carcinomas [3]. In
NSCLC, SP142 antibody has been shown to measure TC and IC. While
response was seen regardless of PD-L1 expression, extension of overall
survival was significantly longer in patients with higher PD-L1 ex-
pression level [6]. Secondly, we used a uniform threshold for the as-
sessment of PD-L1 positivity, as recently 2 different thresholds (using
22c3 antibody) were introduced for the NSCLC treatment decision
based on the previous treatments status [38]. Since we used a wide
variety of cancer lineages (both primary and metastatic cancers), we
believe that a single antibody (SP142) and single threshold (5%) is best
suited for such comparative study, when no outcome data were mea-
sured. However, comparisons between the same histotypes (e.g. pri-
mary squamous vs. metastatic or primary adenocarcinoma vs. meta-
static) was limited by a small number of each histotype. Thirdly, a
significant proportion of the assays was performed on small biopsies.
Although biopsy type (small vs. surgical) in our study had no a sig-
nificant impact on PD-1, PD-L1 and CD8 expressions, this issue should
be taken into account and results cautiously interpreted, as shown in
one previous study [39].
In conclusion, our study revealed significant differences in the
presence of PD-L1 expressing cells in the microenvironments of primary
NSCLC and carcinomas metastatic to lungs. Additionally, it also con-
firmed potential value in measuring the tumor mutational load, which
may provide for immune checkpoint blockade in selected cases.
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